Media Contact Information For more information or interviews with Helen Bligh, please contact: Contact: Nicola Rowley Phone: 07932 656685 Email: [email protected] ######
The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks
This weakening can increase the risk of injuries, such as tendon ruptures, which may complicate recovery and prolong discomfort
Riganti, C., Gazzano, E., Polimeni, M., Aldieri, E